We have previously identified a higher rate of expression of CLDN18.2 in colitis-associated colorectal carcinomas with loss of intestinal markers such as SATB2, and the findings suggested colitis-associated colorectal carcinomas are promising candidates for CLDN18.2 targeted therapy [23]. This evidence concerns the gene SATB2 and colitis.